Browse
Prediction results retrieved after performance evaluation of WHO approved 34 primers to estimate their binding affinities for 3892 SARS-CoV-2 variants.

Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used
  
FK.1.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26650.4US
B.1.544NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26650.4US
AY.75 (Delta)NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26650.4US
HK.3.2NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26650.4US
FK.1.3NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26650.4US
FK.1.5NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26650.4US
HN.8NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26650.4US
B.1.330NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26650.4US
FK.1.3.2NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26650.4US
JL.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26650.4US
FK.1.4.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26650.4US
B.1.36.39NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26650.4US
B.1.1.289NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26650.4US
FK.1.2.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26650.4US
FK.1.3.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26650.4US
FK.1.2.2NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26650.4US
FK.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26650.4US
FK.1.1.2NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26650.4US
FK.1.2NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26650.4US
CH.1.1.17NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26650.4US
BA.5.6.3NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26650.4US
B.1.36.17NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26650.4US
XBB.1.5.64NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26650.4US
AY.91 (Delta)NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26650.4US
B.1.36.18NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26650.4US
HV.1.10SChan-SCCTACTAAATTAAATGATCTCTGCTTTACT30302271222741F-26522.1China
BQ.1.1.62NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
GA.7NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
FL.23NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XBB.2.3.13NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.160NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
JV.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XCYNSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
HK.16NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
JN.1.1.4NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
EK.4NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
HV.1.10NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
HV.1.6.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
EF.1.2NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BU.3NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BA.5.1.38NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BA.5.2.34NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
CJ.1.2NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BQ.1.1.21NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BA.4.6.3NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
CM.7.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BA.5.3.3NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BQ.1.22NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BF.7.19NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
FA.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used